Derivation of Tumor Specific Hybridomas

Glioblastoma Clinical Trial

Official title:

Vaccination of Patients With Newly Diagnosed Glioblastoma Using Autologous Tumor Lysate and Montanide Emulsion for Derivation of Tumor Specific Hybridomas

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01702792
• Other study ID #: W12209
• Status: Terminated
• Phase: Phase 1
• First received: October 3, 2012
• Last updated: April 2, 2018
• Start date: January 2014
• Est. completion date: May 6, 2015

Study information

• Verified date: April 2018
• Source: Dartmouth-Hitchcock Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a non-randomized, open-label study in patients with newly diagnosed glioblastoma to determine the ability to generate human hybridomas from lymph nodes draining an autologous tumor vaccine injection and demonstrate that the hybridomas secrete glioblastoma-specific antibodies.

Description:

The intradermal vaccine will be injected 20cm in the anterior thigh. Vaccination will be done twice and separated by one week. The first vaccination will be performed approximately 2 weeks after surgery.

Approximately one week after the second vaccination one or two vaccine-draining lymph node(s) will be removed. The lymph node(s) will be identified using SN technology. One or two lymph node(s) will be removed.

Lymph nodes will be processed for recovery of B cells and formation of hybridomas.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: May 6, 2015
• Est. primary completion date: May 6, 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with confirmed new diagnosis of glioblastoma and who have a yield of at least 8x10(7) tumor cells obtained at the time of surgery

• Age > 18 years

• KPS Score of greater than or equal to 70

• Adequate bone marrow as evidenced by:

Absolute lymphocyte count > 1,000/uL Platelet count > 50,000/uL

• Adequate renal function as evidenced by serum creatinine < 2.0

• Patients must be able to read, understand and provide informed consent to participate in the trial.

• Patients of childbearing potential must agree to use an effective form of contraception during the study and for 90 days following vaccination (an effective form of contraception is an oral contraceptive or a double barrier method)

Exclusion Criteria:

A patient may not be enrolled in the trial if any of the following criteria are met:

• Patients receiving dexamethasone > 8 mg/day during the week before vaccination.

• Patients who are pregnant or lactating

• Patients with active second malignancy.

• Any other medical conditions, including mental illness or substance abuse, deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results.

Related Conditions & MeSH terms

• Glioblastoma

Intervention

Biological:
• Tumor Vaccine
Tumor cells obtained at the time of surgery are irradiated with 10,000 Gy and freeze fractured. Lysate at 1x107 tumor cell equivalent (TCE) will be used for vaccination with adjuvant, Montanide ISA 51 VG.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Dartmouth-Hitchcock Medical Center	University of Vermont

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Tumor Binding Characteristics	Exploratory objectives will include: Determining the rate of tumor binding antibodies from hybridomas derived from circulating B cells.; Determining the tumor-binding profile of antibodies present in the blood.	6 months
Primary	number of hybridoma clones that produce anti-glioma antibodies	The primary technical endpoint demonstrating the feasibility of the pilot study will be based upon the total count of the number of generated hybridoma clones sourced from the dermal vaccine draining lymph nodes that are determined to be producing anti-glioma antibodies.	6 months
Secondary	Production of Antibodies	Secondary outcomes will include: Determining how many hybridoma clones produce glioblastoma-specific antibodies. The initial secondary endpoint will include the counting of the number of hybridoma clones sourced from the dermal vaccine draining lymph nodes that generate specific glioma antibodies.	6 months
Secondary	Toxicity of Vaccine	• Determining toxicity of vaccine	6 months
Secondary	Clone Production Rate	Determining whether B cells sourced from the vaccine nodes produce more anti-tumor antibody hybridomas than the non-vaccine node. The rate of producing these clones will be compared according to the source of the B cells. Thus, B cells recovered from vaccine related nodes will be compared to B cells recovered from the non-vaccine node.	6 months
Secondary	Lymph Node Biopsy	Determine the safety and toxicity issues related to the Lymph Node Biopsy	6 months